In a positive year for the region's banks, 2025 ECM fees in Apac, ex Japan, were up 45% from 2024, DCM fees saw 11% growth, amid a record year for bonds, while M&A advisory fees climbed 43%.

The HK$155 a share offer is a 33% premium over Hang Seng's 30-day average closing price; HSBC already owns 63% of the HKEX-listed bank. Hang Seng's after tax profits declined 30% in H1 2025. HSBC has paused buybacks.

Hong Kong-listed biotech firms are outperforming as Trump’s policies cause firms to change course from their traditional US destination, with more HKEX listings expected in the second half of 2025; experts shared their views at BIOHK.

The rationale behind all the winners in mainland China, Hong Kong, Mongolia, South Korea and Taiwan.

The firm saw net asset values decline across the financial year, however net property income and revenues grew, with high occupancy rates amid challenging conditions.

An April review by the IMF ended without an agreement, with June the next opportunity to meet the IMF's conditions and release two tranches of loans.

The games, if they go ahead, potentially in 2027, are expected to bring economic benefits to the Greater Bay Area, including Hong Kong, and countries part of the Belt and Road Initiative.

US president Donald Trump has ordered a 90-day pause on retaliatory tariffs above the 10% already imposed, except for Chinese goods, with tariffs now at 145% after China retaliated; Trump has now put tariff exemptions on smartphones, electronics and computers.

The $400m deal will see global PE firm acquire up to 54% of equity from CVC, and up to a total 77% stake of the Indian cancer care specialist; KKR made several significant investments into Indian healthcare firms last year, as regional PE deals bounceback.